Home / Business and Economy / Bayer Pharma Eyes 30% Margin by 2030
Bayer Pharma Eyes 30% Margin by 2030
14 Jan
Summary
- Bayer Pharma aims for mid-single-digit growth by 2027.
- Operating margins targeted at 30% by 2030.
- New medicines like Nubeqa and Asundexian will fuel growth.
Bayer's pharmaceuticals division is targeting a return to mid-single-digit percentage growth by 2027. Stefan Oelrich, head of the division, announced that operating margins are expected to reach approximately 30% by 2030, with an upward trend beginning in 2028. This strategic push follows the impact of patent expirations on key drugs like Xarelto.
The future growth trajectory for Bayer's pharmaceuticals hinges on its pipeline of newer medications. These include promising treatments such as Nubeqa for prostate cancer, Kerendia for kidney conditions, Beyonttra for heart issues, and Lynkuet for menopausal symptoms. Additionally, the anticoagulant Asundexian is a significant focus, having recently shown positive results in a stroke study.
Despite past investor skepticism, Bayer expresses confidence in its pharmaceutical business's resilience. The company reaffirmed its 2025 financial targets, forecasting currency- and portfolio-adjusted sales growth between 0% and 3% and an adjusted operating profit margin of 24% to 26%. This outlook underscores Bayer's commitment to navigating challenges and achieving future success.
